Molecular Tumor Boards: current practice and future needs-Reference-Cited by-同舟云学术

Molecular Tumor Boards: current practice and future needs

Published:2017-12 Issue:12 Volume:28 Page:3070-3075
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

van der Velden D.L.,van Herpen C.M.L.,van Laarhoven H.W.M.,Smit E.F.,Groen H.J.M.,Willems S.M.,Nederlof P.M.,Langenberg M.H.G.,Cuppen E.,Sleijfer S.,Steeghs N.,Voest E.E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/12/3070/22295547/mdx528.pdf

Reference40 articles.

1. Genomics-driven oncology: framework for an emerging paradigm;Garraway;J Clin Oncol,2013

2. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033;Blanke;J Clin Oncol,2008

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

4. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways;Critical Reviews in Oncology/Hematology;2024-07

2. The value of virtual molecular tumor boards for informed clinical decision-making;The Oncologist;2024-05-18

3. Das Verbundprojekt „Personalisierte Medizin für die Onkologie“ (PM4Onco) als Teil der Medizininformatik-Initiative (MII);Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz;2024-05-13

4. Evaluation of Artificial Intelligence (AI)-basedin silicotools for variant classification in clinically actionable NSCLC variants;2024-04-14

5. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India;JCO Global Oncology;2024-03